Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Are active surveillance criteria sufficient for predicting advanced stage prostate cancer patients?

Ongun S, Celik S, Gül-Niflioglu G, Aslan G, Tuna B, Mungan U, Uner S, Yörükoğlu K.

Actas Urol Esp. 2014 Oct;38(8):499-505. doi: 10.1016/j.acuro.2013.11.005. Epub 2014 Mar 16. English, Spanish.

PMID:
24646919
2.
3.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.

4.

Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

J Urol. 2014 Feb;191(2):350-7. doi: 10.1016/j.juro.2013.09.034. Epub 2013 Sep 23.

PMID:
24071481
5.

Pathological stage distribution in patients treated with radical prostatectomy reflecting the need for protocol-based active surveillance: results from a contemporary European patient cohort.

Seiler D, Randazzo M, Klotz L, Grobholz R, Baumgartner M, Isbarn H, Recker F, Kwiatkowski M.

BJU Int. 2012 Jul;110(2):195-200. doi: 10.1111/j.1464-410X.2011.10707.x. Epub 2011 Nov 17.

6.

Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis.

Reese AC, Landis P, Han M, Epstein JI, Carter HB.

J Urol. 2013 Dec;190(6):2033-8. doi: 10.1016/j.juro.2013.05.015. Epub 2013 May 13.

PMID:
23680308
7.

Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.

Oh JJ, Hong SK, Lee JK, Lee BK, Lee S, Kwon OS, Byun SS, Lee SE.

BJU Int. 2012 Dec;110(11 Pt B):E494-9. doi: 10.1111/j.1464-410X.2012.11182.x. Epub 2012 Apr 30.

8.

A solitary positive prostate cancer biopsy does not predict a unilateral lesion in radical prostatectomy specimens.

Koie T, Mitsuzuka K, Narita S, Yoneyama T, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C.

Scand J Urol. 2015 Apr;49(2):103-7. doi: 10.3109/21681805.2014.951959. Epub 2014 Aug 28.

PMID:
25165894
9.

Is active surveillance a safe alternative in the management of localized prostate cancer? Pathological features of radical prostatectomy specimens in potential candidates for active surveillance.

Norman Z, Militza P, Andres F, Daniela F, Alejandro M, Catherine S, Juan F.

Int Braz J Urol. 2014 Mar-Apr;40(2):154-9. doi: 10.1590/S1677-5538.IBJU.2014.02.04.

10.

Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?

Chen DJ, Falzarano SM, McKenney JK, Przybycin CG, Reynolds JP, Roma A, Jones JS, Stephenson A, Klein E, Magi-Galluzzi C.

BJU Int. 2015 Aug;116(2):220-9. doi: 10.1111/bju.12880. Epub 2014 Dec 15.

11.

Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.

Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y.

BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x. Epub 2013 Jan 15.

12.

Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).

El Hajj A, Ploussard G, de la Taille A, Allory Y, Vordos D, Hoznek A, Abbou CC, Salomon L.

BJU Int. 2013 Jan;111(1):53-9. doi: 10.1111/j.1464-410X.2012.11276.x. Epub 2012 Jun 21.

13.

Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.

Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, Dorey F, Terris MK; SEARCH Database Study Group.

Urology. 2003 Apr;61(4):742-7.

PMID:
12670558
14.

Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms.

Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW.

Urology. 2003 Mar;61(3):589-95.

PMID:
12639653
15.

Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy.

Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, Salonia A, Scattoni V, Rigatti P, Montorsi F, Briganti A.

BJU Int. 2012 Jul;110(2 Pt 2):E64-8. doi: 10.1111/j.1464-410X.2011.10762.x. Epub 2011 Nov 17.

17.

Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: correlation with findings at radical prostatectomy and prognosis.

Ellis CL, Partin AW, Han M, Epstein JI.

J Urol. 2013 Dec;190(6):2068-73. doi: 10.1016/j.juro.2013.05.056. Epub 2013 May 30.

PMID:
23727307
18.

Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?

Jin BS, Kang SH, Kim DY, Oh HG, Kim CI, Moon GH, Kwon TG, Park JS.

Korean J Urol. 2015 Sep;56(9):624-9. doi: 10.4111/kju.2015.56.9.624. Epub 2015 Sep 2.

19.

Heterogeneity in D'Amico classification-based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility.

Schiffmann J, Wenzel P, Salomon G, Budäus L, Schlomm T, Minner S, Wittmer C, Kraft S, Krech T, Steurer S, Sauter G, Beyer B, Boehm K, Tilki D, Michl U, Huland H, Graefen M, Karakiewicz PI.

Urol Oncol. 2015 Jul;33(7):329.e13-9. doi: 10.1016/j.urolonc.2015.04.004. Epub 2015 May 7.

PMID:
25960411
20.

Supplemental Content

Support Center